MyFinsight
Home
Blog
About
Contact
Download
Download image
Xywav
$408,200K
(18.39%↑ Y/Y)
Xyrem
$31,200K
(-16.22%↓ Y/Y)
Rylaze Enrylaze
$103,700K
(10.05%↑ Y/Y)
Zepzelca
$101,000K
(60.23%↑ Y/Y)
Defitelio Defibrotide
$47,400K
(16.57%↑ Y/Y)
Modeyso
$41,400K
Vyxeos
$26,600K
(-9.96%↓ Y/Y)
Ziihera
$13,300K
(573.42%↑ Y/Y)
Revenue From Contract
With Customer...
$249,800K
(14.73%↑ Y/Y)
Sleep
$439,400K
Oncology
$333,400K
Epilepsy
$249,800K
Other Products
$2,700K
(-43.54%↓ Y/Y)
Product And Services
Product Sales Net Of...
$1,025,300K
(22.14%↑ Y/Y)
High Sodium
AGOxybate Product Royalty...
$36,300K
(-25.84%↓ Y/Y)
Other Royalty And
Contract Revenues
$7,300K
Total revenues
$1,068,900K
(19.05%↑ Y/Y)
Income (gain) from
operations
$336,600K
(702.23%↑ Y/Y)
Foreign exchange gain
(loss)
$2,500K
(1273.71%↑ Y/Y)
Total operating
expenses
$732,300K
(-23.22%↓ Y/Y)
Gain on sale of
priority review voucher
$122,800K
Income (gain) before
income tax expense...
$299,200K
(372.47%↑ Y/Y)
Interest expense, net
-$39,900K
(25.71%↑ Y/Y)
Selling, general and
administrative
$352,700K
(-31.38%↓ Y/Y)
Research and development
$196,000K
(8.50%↑ Y/Y)
Intangible asset
amortization
$172,300K
(11.56%↑ Y/Y)
Cost of product sales
(excluding amortization of...
$134,100K
(28.18%↑ Y/Y)
Net income (gain)
$293,100K
(416.72%↑ Y/Y)
Income tax expense
(benefit)
$6,100K
(134.25%↑ Y/Y)
Back
Back
Income Statement
Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ)
source: myfinsight.com